Re N Tox™

About Re N Tox™ — Pharma Research Bio’s Botulinum Toxin Type A

Re N Tox™ is produced by Pharma Research Bio Co., Ltd., a South Korean biopharmaceutical company based in Gyeonggi-do. The active substance is Clostridium botulinum toxin type A, supplied as a freeze-dried powder for reconstitution before intramuscular injection. Manufacturer- and distributor-reported specifications place the molecular weight at approximately 927 kDa and purity at approximately 99.6%. Both figures are consistent with a formulation that retains its native complexing proteins rather than isolating the 150 kDa neurotoxin.[1]

Pharma Research Bio developed and evaluated its formulation for moderate to severe glabellar lines, and it received regulatory approval in South Korea. Practitioners comparing Re N Tox™ to BOTOX® should refer to destination-market package inserts and official prescribing information for clinical data rather than relying on distributor-published comparisons.

Re N Tox™ Products — 100U and 200U

The Re N Tox™ 100 vial is the everyday format for single-patient facial aesthetic sessions. Applications commonly discussed in listings for Korean botox products like Re N Tox™ include glabellar lines, forehead rhytids, crow’s feet, brow lift, masseter contouring, and lip flip. Practitioners planning glabellar-line dosing should follow the destination-market package insert for unit distribution and injection-point patterns, not reseller-published protocols.

The Re N Tox™ 200 vial doubles the neurotoxin capacity in the same lyophilized formulation. Clinics running multi-area sessions, higher patient throughput, or higher-unit therapeutic protocols such as hyperhidrosis or blepharospasm, where regulation permits, often prefer this format for cost-per-unit efficiency and reconstitution economy. Both presentations follow the same handling and cold-chain considerations.

Protein-Free Formulation, Diffusion, and Immunogenicity

Reported specifications place Re N Tox™ in the same broad category as BOTOX®, BOTULAX®, and NABOTA®: botulinum toxin type A formulations with intact complexing proteins.[1] It does not sit in the protein-free class occupied by XEOMIN® and BOCOUTURE®. Some listings additionally reference toxin type A human serum albumin as a stabilizer, which is standard across many BTX-A products rather than a unique differentiator.

A peer-reviewed review of the spread of botulinum toxins found that injection volume, dilution ratio, dose, and placement technique are the principal factors governing spread in local areas of the skin, and that molecular weight and complexing-protein content do not meaningfully alter diffusion across ~900 kDa complexed products.[2] Technique parameters and target anatomy carry more weight than any single formulation trait, so “controlled diffusion” claims read as commercial positioning rather than an established pharmacological advantage.

Neutralizing antibody formation is uncommon with modern BTX-A products but can occur with repeated exposure over time, particularly in higher cumulative-dose settings. This is a class-wide consideration rather than a Re N Tox™ specific one.[1]

Re N Tox™ Dilution and Reconstitution

Re N Tox™ dilution follows the general lyophilized-BTX-A workflow. Add sterile, preservative-free 0.9% saline slowly along the vial wall to limit foaming, and rotate the vial gently until the powder dissolves. Avoid vigorous shaking, since agitation can denature the neurotoxin protein.

Two commonly cited dilution volumes for the 100U vial:

Storage guidance from manufacturer and distributor documentation is straightforward. Refrigerate unopened vials at 2°C to 8°C. Reconstituted solution refrigerated between injections and used within 24 hours. Do not freeze.

Do not assume unit interchangeability across BTX-A products. Published conversion ratios for XEOMIN® or JEUVEAU® cannot be extrapolated to Re N Tox™ without dedicated bioequivalence data, and individual patient response with local prescribing information should always take precedence over a fixed conversion figure.[1]

Indications and Injection Sites for Re N Tox™

Re N Tox™ is discussed across both aesthetic and, in some markets, therapeutic contexts. Its mechanism is temporary muscle relaxation via presynaptic acetylcholine blockade, distinct from the volumizing effect of a filler.

Common aesthetic applications include glabellar lines in the forehead between the eyebrows, horizontal forehead rhytids, lateral canthal lines (crow’s feet), brow lift, masseter contouring, and lip flip. Therapeutic uses referenced in the broader Korean BTX-A literature include excessive sweating (hyperhidrosis) and blepharospasm; availability and label status for Re N Tox™ specifically are jurisdiction-dependent, and the 200U format offers dosing headroom where those higher-unit protocols are authorized.

The periorbital and perioral regions are where “low diffusion” claims surface most often in marketing. Whether the formulation contributes independently to a tighter spread is not well established, so injection volume, needle depth, placement pattern, and dilution remain the primary levers a practitioner controls.

Full Re N Tox™ Product Range

• Re N Tox™ 100U — lyophilized botulinum toxin type A, 100 units per vial, MFDS-registered for export.
• Re N Tox™ 200U — lyophilized botulinum toxin type A, 200 units per vial, MFDS-registered for export.

No additional vial size, including a 50-unit format, appears in current listings. Availability should still be confirmed on the live Doctor Medica website, since distributor ranges shift with market authorization and stock updates.

How Re N Tox™ Compares to Other Botulinum Toxin Type A Brands

vs NABOTA®

NABOTA® is manufactured by Daewoong Pharmaceutical and marketed in the United States as JEUVEAU® (prabotulinumtoxinA), which received FDA approval for aesthetic use in 2019.[3] Re N Tox™ carries neither FDA approval nor a formally verified CE mark. Both are botulinum toxin type A products with complexing proteins retained. For US practitioners, JEUVEAU® is the FDA-cleared route to a Korean-origin toxin; Re N Tox™ is not.

vs LIZTOX®

LIZTOX® (Huons) is another South Korean botulinum toxin type A product positioned for international export. It sits in the same complexed-protein category as Re N Tox™, and neither benefits from published RCT-level head-to-head data against the other. LIZTOX® has expanded into several European and Asian markets. Weighing the two comes down to labeling, batch documentation, and destination-market authorization, not assumed clinical equivalence.

vs BOTULAX®

BOTULAX® is Hugel’s flagship botulinum toxin type A product, distributed widely across international markets. Hugel’s related molecule LETYBO® holds FDA approval; BOTULAX® itself does not. Re N Tox™ and BOTULAX® are both lyophilized powders requiring reconstitution, and both retain complexing proteins, so the meaningful differences lie in the manufacturer, regulatory footprint, and authorization level. LETYBO®’s FDA clearance does not extend to international BOTULAX® presentations or to Re N Tox™.

vs LETYBO®

LETYBO® (letibotulinumtoxinA) received FDA approval in 2024 for temporary improvement of moderate to severe glabellar lines in adults.[3] Manufactured by Hugel, LETYBO® is a distinct molecule from Re N Tox™, which comes from Pharma Research Bio and lacks FDA authorization. In the US market, LETYBO® is the relevant FDA-approved Korean BTX-A; Re N Tox™ is not an equivalent substitute there.

vs INNOTOX®

The most visible workflow difference here is presentation. INNOTOX® (Medytox) is supplied as a ready-to-use liquid formulation, so reconstitution is unnecessary before injection. Re N Tox™ is a lyophilized powder requiring saline dilution. That gap primarily affects preparation and handling, not treatment outcomes. Neither product currently has FDA aesthetic approval, and comparisons of efficacy or duration should be based on each product’s own clinical data.

Regulatory Status and Safety Profile

Re N Tox™ is manufactured in South Korea under GMP-compliant production standards and is not FDA-approved for use in the United States.[3] In South Korea, export-designated lots faced regulatory enforcement by the Ministry of Food and Drug Safety (MFDS) in late 2021 regarding indirect export distribution practices. Pharma Research Bio challenged the administrative action, securing injunctions and a favorable first-instance ruling from the Seoul Administrative Court overturning the revocation orders, with the regulatory dispute proceeding to higher courts.[4] Because registration, import licensing, and market authorization vary significantly worldwide, practitioners must verify current local authorization and source documentation directly with their supplier before ordering.

Class-wide side effects and precautions relevant to Re N Tox™ include injection-site bruising, tenderness, headache, and mild swelling. Diffusion into adjacent muscles can produce asymmetry, brow heaviness, or eyelid ptosis, particularly around the periorbital area and other delicate local areas of the skin. These outcomes reflect anatomy, dose, dilution, injection volume, placement, and injector technique rather than any intrinsic low-diffusion property of the product.[2]

Contraindications include known hypersensitivity to botulinum toxin or excipients, active infection at the intended injection site, and neuromuscular junction disorders. Use in pregnancy, lactation, or in patients taking medicines that affect neuromuscular transmission requires case-by-case clinical judgment. Verify vial integrity, cold-chain storage history, and authorized product information before every treatment session.

Where to Buy Re N Tox™ Online

Re N Tox™ is a prescription pharmaceutical and reaches licensed medical professionals only through authorized distribution. Clinics evaluating where to buy Re N Tox™ online typically weigh distributor credentials, documentation, and storage handling ahead of price. Baseline verification should cover:

• Distributor licensing to handle prescription BTX-A stock in the destination country
• Cold-chain shipping protocols with temperature logging, since lyophilized toxin is transit-sensitive
• LOT number documentation and certificates of authenticity per shipment
• Import and prescription-only requirements specific to the practitioner’s own jurisdiction

Re N Tox™ reviews on open marketplaces frequently attribute clinical outcomes to a specific import channel; any single Re N Tox™ review is anecdotal and not a substitute for verifiable supplier documentation. To purchase Re N Tox™ online through appropriate channels, licensed practitioners can request sourcing information from Doctor Medica’s staff.

How to Buy Re N Tox™ Wholesale

Wholesale procurement follows a stricter verification path than single-vial ordering. Clinics that buy Re N Tox™ wholesale should expect distributors to require proof of medical licensure and appropriate corporate documentation before opening an account. From the practitioner side, cold-chain documentation across the full shipment chain, minimum-order thresholds, and vial-configuration availability (100U or 200U) all deserve a written record with the supplier.

Verification Steps Before You Order Re N Tox™ Wholesale

Shipping temperature is the most common source of stability concern for lyophilized BTX-A products, so any decision to order Re N Tox™ wholesale should be conditional on documentation confirming continuous refrigeration between 2°C and 8°C from the origin warehouse through last-mile delivery. Because Re N Tox™ carries MFDS-linked export authorization rather than FDA clearance, import eligibility depends on the practitioner’s regional regulatory framework, and destination-market prescribing rules should be checked against each shipment’s paperwork before administration.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Frequently Asked Questions

Who manufactures Re N Tox™?

Re N Tox™ is manufactured by Pharma Research Bio Co., Ltd., a subsidiary of PharmaResearch Co., Ltd., based in South Korea. It is not a Hugel product and should not be confused with BOTULAX® or LETYBO®, which come from a different manufacturer.

How does Re N Tox™ relate to XEOMIN® and BOCOUTURE® molecularly?

Available manufacturer- and distributor-reported data place Re N Tox™ in the standard complexed-protein botulinum toxin type A category alongside BOTOX®, BOTULAX®, and NABOTA®. It has not been assigned the incobotulinumtoxinA INN and should not be treated as interchangeable with XEOMIN® or BOCOUTURE® on the basis of reseller copy alone. Its regulatory history in South Korea, including the 2021 MFDS indirect-export enforcement action and the subsequent Seoul Administrative Court ruling in Pharma Research Bio’s favor, is another reason to rely on the official manufacturer monograph rather than third-party marketing claims.[4]

Is Re N Tox™ FDA-approved for the US market?

No. Re N Tox™ is registered in South Korea for export and does not appear on the FDA’s approved botulinum toxin list for the United States.[3] Practitioners should confirm the applicable label and regulatory status in their own jurisdiction before ordering.

What saline volume is used for Re N Tox™dilution?

For the 100U vial, two commonly cited protocols are 2.5 mL of preservative-free 0.9% saline for approximately 4 Units per 0.1 mL, or 5 mL for approximately 2 Units per 0.1 mL. Rotate the vial gently rather than shaking, refrigerate between uses, and discard within 24 hours of reconstitution.

Which treatment areas is Re N Tox™ used for?

Aesthetic applications commonly discussed include glabellar lines, forehead rhytids, crow’s feet, brow lift, masseter contouring, and lip flip. Therapeutic uses in the Korean literature include excessive sweating and blepharospasm, with the Re N Tox™200 units format offering more capacity for higher-dose protocols where regulation permits.

What side effects and precautions apply to Re N Tox™?

Class-wide reactions include bruising, tenderness, mild swelling, and headache. Uncommon complications such as eyelid ptosis relate mainly to injection placement and technique. Contraindications include neuromuscular junction disorders, active infection at the injection site, and known hypersensitivity to botulinum toxin.

How can practitioners get sourcing information for Re N Tox™?

Licensed medical professionals can contact Doctor Medica’s staff for guidance on documentation, cold-chain shipping, verified distributor arrangements, and jurisdiction-specific licensing considerations.

Citations and Resources

[1] Frevert, Jürgen, and Dirk Dressler. “Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?.” Biologics : targets & therapy vol. 4 325-32. 9 Dec. 2010, doi:10.2147/BTT.S14902

[2] Brodsky, Matthew A et al. “Diffusion of botulinum toxins.” Tremor and other hyperkinetic movements (New York, N.Y.) vol. 2 (2012): tre-02-85-417-1. doi:10.7916/D88W3C1M

[3] U.S. Food and Drug Administration. “Drug Approvals and Databases.” U.S. Food and Drug Administration, www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases.

[4] Kim, Chan-hyuk. “Permit Cancellation of Pharma Research Bio’s Botulinum Toxin to Hit LG Chem.” Korea Biomedical Review, 11 Nov. 2021, www.koreabiomed.com/news/articleView.html?idxno=12534.

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.

Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.